Brief: RaQualia Pharma says license agreement for novel P2X7 receptor antagonist

RaQualia Pharma

26/03/2018 07:50

March 26(Reuters) - RaQualia Pharma Inc  4579.T 
    
    * Says it and Asahi Kasei Pharma Corp have entered into a
license
agreement for a novel P2X7 receptor antagonist discovered
through a research collaboration between the two companies

    
    
    Source text in Japanese:https://goo.gl/TJ8sZH
    Further company coverage: 4579.T 

 (Beijing Headline News)
 ((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))